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The integration characteristics of retroviral (RV) vectors 
increase the probability of interfering with the regula-
tion of cellular genes, and account for a tangible risk 
of insertional mutagenesis in treated patients. To assess 
the potential genotoxic risk of conventional or self-
 inactivating (SIN) γ-RV and lentiviral (LV) vectors indepen-
dently from the biological consequences of the insertion 
event, we developed a quantitative assay based on real-
time reverse transcriptase—PCR on low-density arrays 
to evaluate alterations of gene expression in individual 
primary T-cell clones. We show that the Moloney leuke-
mia virus long terminal repeat (LTR) enhancer has the 
strongest activity in both a γ-RV and a LV vector context, 
while an internal cellular promoter induces deregulation 
of gene expression less frequently, at a shorter range and 
to a lower extent in both vector types. Downregulation 
of gene expression was observed only in the context of 
LV  vectors. This study indicates that insertional gene acti-
vation is determined by the characteristics of the tran-
scriptional regulatory elements carried by the vector, and 
is largely independent from the vector type or design.
Received 2 October 2008; accepted 22 February 2009; published online 
17 March 2009. doi:10.1038/mt.2009.51
IntroductIon
Retroviral (RV) vectors were considered safe until lymphoprolif-
erative disorders were reported in five patients undergoing gene 
therapy for X-linked severe combined immunodeficiency.1,2 In at 
least four of these patients, a RV vector derived from the Moloney 
murine leukemia γ-retrovirus (MLV) inserted into, and activated, 
the LMO2 T-cell proto-oncogene in hematopoietic progenitors.3 
Recent studies showed that γ-RV vectors integrate preferentially 
around promoters and CpG islands,4 where the insertion of tran-
scriptional enhancers contained in the viral long terminal repeats 
(LTRs) has a high probability of interfering with gene regulation. 
RV vectors have a high propensity to target proto-oncogenes and 
genes involved in cell proliferation and signaling,5 the activation 
of which may lead to clonal skewing or expansion of hematopoi-
etic progenitors in animals6 as well as in patients.7–9 However, no 
adverse effects have been reported in other clinical trials with 
retrovirally transduced hematopoietic cells,10–12 suggesting that 
disease-, vector-, or transgene-specific factors may cooperate with 
insertional gene activation in inducing malignant or premalignant 
transformation.13
The use of human immuno-deficiency virus (HIV)-derived 
lentiviral (LV) vectors is expected to increase the safety profile of 
genetically modified hematopoietic cells. Compared to RV  vectors, 
LV vectors do not favor integration in the proximity of regulatory 
elements4 or growth-controlling genes,5 and are associated with a 
lower frequency of tumor induction in vivo.14 However, tumorige-
nicity is highly dependent on the choice of the experimental model, 
and it is not necessarily predictive of the potential consequences of 
vector integration in different clinical contexts. Assessing the over-
all frequency by which an integrated provirus leads to deregulation 
of gene expression in a target cell provides an additional readout 
of its potential genotoxicity, which is independent from the bio-
logical consequences of the insertion event, e.g., clonal selection 
or tumor induction. We developed a quantitative assay to evaluate 
the expression of genes within a window of 200 kb from the inser-
tion site of different RV and LV vectors in randomly selected, indi-
vidual T-cell clones. We show that the nature of the transcriptional 
enhancer is more relevant than the vector type in perturbing gene 
expression in primary hematopoietic cells.
results
Analysis of rV integration sites in t-cell clones
Cord blood or peripheral blood mononuclear cells were trans-
duced at a multiplicity of infection of 10–25 with preparations of 
MLV- and HIV-derived vectors expressing a green fluorescent pro-
tein (GFP) gene from a wild-type LTR or from an internal viral 
[cytomegalovirus (CMV), MLV LTR] or cellular [phosphoglycerate 
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kinase (PGK)] promoter in a ΔU3, self-inactivating (SIN) design 
(Figure 1). T-cell clones were obtained from transduced cultures 
by limiting dilution cloning (0.3–1 cell/well). RV integration sites 
in randomly selected GFP+ clones were sequenced by linker-
 mediated (LM) PCR and mapped onto the human genome. T-cell 
clones transduced by RV or LV vectors contained on average 1.1 and 
2.2 independent integrations per cell, respectively (range: 1–5 and 
1–7). To estimate the resolution power of one-enzyme LM-PCR in 
our clones we performed a Southern blot analysis on eight T-cell 
clones transduced with SIN LVs, used in this study, and com-
pared it with the number of integration sites mapped by LM-PCR 
(Supplementary Figure S2). As shown, the number of integrations 
mapped by LM-PCR (Supplementary Figure S2c) underestimates 
only slightly the number of the integrated  proviruses represented 
in the Southern blot (Supplementary Figure S2b), indicating that 
although we did not fully map the proviruses in each clone, the 
LM-PCR technique with one enzyme provides a nice estimate of 
the copy number of the proviruses integrated in a single clone.
rV and lV vectors induce deregulation of gene 
expression in t cells
RNA was extracted from each T-cell clone, and the expression of 
Known Genes (UCSC definition) in a window of ±100 kb from 
each insertion site (Figure 2a) analyzed by quantitative reverse 
transcriptase–PCR on custom 7,900 TaqMan low-density arrays, 
with specific primers designed and validated by the manufacturer 
(Applied Biosystems, Foster City, CA). For each vector, we analyzed 
the expression of 50–106 genes flanking 34–53 integrated proviruses 
in 14–45 independent T-cell clones (Figure 1). Expression of each 
gene was determined in quadruplicate reactions on the same array 
in the test clone (the one with an integration at a distance of <100 kb 
from the gene) and in 10–31 control clones. Expression levels were 
measured as relative mRNA quantity (RQ) after normalization for 
the level of glyceraldehyde-3-phosphate dehydrogenase, and plot-
ted as log2 variation from the median levels. The complete results 
of this analysis are shown in Supplementary Figure S1a–f. Genes 
showing RQ values significantly higher or lower than the average 
values in the control clones (z-score >2.81 or <–2.81, P < 0.005) are 
reported in Figure 2b. For each gene (x-axis), expression values in 
the test clones are indicated by red dots and those for the control 
clones by black dots. The average expression level of each gene in 
mock transduced bulk population of T cells was determined also 
by Affymetrix microarray analysis, and is indicated on the x-axis 
by color-coded symbols (black: no expression; blue: low expression; 
yellow: intermediate expression; red: high expression). This mea-
sure helps to understand whether an inserted provirus deregulates 
genes as active or not at the time of transduction.
All proviruses induced insertional deregulation of gene 
expression in the 200-kb window from the integration site, 
although with different frequencies. The HIV LTR upregulated 
3/50 tested genes (6.0%), the internal CMV promoter 2/69 genes 
(2.9%), and the internal PGK promoter 4/106 genes (3.7%) in 
a SIN-LV context and 3/94 genes (3.2%) in a SIN-RV context 
(Figure 2b). The frequency of upregulated genes decreases sig-
nificantly if only the z-scores >3.29 (P < 0.001) are considered 
(Table 1). On the contrary, the MLV LTR upregulated genes at 
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Figure 2 retroviral (rV) and lentiviral (lV) vectors deregulate gene 
expression in t-cell clones. (a) Schematic representation of the genomic 
annotation window around the viral insertion site. Introns are represented 
by thick horizontal bars, exon by vertical bars. (b) Quantitative PCR analy-
sis of the expression of genes significantly (P < 0.005) up- or downregu-
lated in a ±100-kb window around the integration sites of RV and LV 
vectors in individual T-cell clones. Expression levels (y-axis) were measured 
as relative mRNA quantity (RQ) after normalization for the level of glyc-
eraldehyde-3-phosphate dehydrogenase, and plotted as log2 variations 
from the median level (0) in all analyzed clones. For each gene (x-axis), 
the expression value in the test clone is indicated by red dots, the expres-
sion values in the control clones (10–31) are indicated by black dots. 
Color-coded symbols on the x-axis indicate the average expression level 
of each gene in proliferating T cells as determined by Affymetrix microar-
ray analysis. Expression values were divided in four classes, i.e., absent 
(black), low (<25th percentile in a normalized distribution, blue), interme-
diate (>25th and <75th percentile, yellow), and high (>75th percentile, 
red). CMV, cytomegalovirus; HIV, human immuno-deficiency virus; MLV, 
Moloney leukemia virus; PGK, phosphoglycerate kinase.
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Figure 1 schematic structure of retroviral and lentiviral vectors: u3, 
r, and u5 regions are indicated in the 5ʹ ltrs. Δ indicates deletion 
of the U3 element. For each vector, the number of analyzed genes in a 
window of ±100 kb from the insertion site, and the number of analyzed 
proviruses (hits) and T-cell clones, are reported. CMV, internal cytomega-
lovirus immediate-early promoter; cPPT, central polypurine tract; HIV, 
human immuno-deficiency virus; LTR, long terminal repeat; MLV LTR, 
internal Moloney leukemia virus LTR; PGK, internal phosphoglycerate 
kinase promoter; RRE, Rev-responsive element.
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a higher frequency, i.e., 4/88 genes (4.5%) in its natural context 
(a wt-LTR MLV vector) and 11/82 genes (13.4%) as an inter-
nal promoter in a SIN-HIV vector (Figure 2b). Upregulation 
was more pronounced (up to 1,000 times) and more consistent 
(P < 0.0001 in 8/15 genes, Table 1) compared to that induced 
by the HIV LTR, CMV, and PGK promoters. Integrated pro-
viruses caused deregulation of gene expression both upstream 
and  downstream from transcription start sites (Figure 3), in 
most cases within a range of ±50 kb. However, 2/11 MLV LTR 
 insertions upregulated gene expression from as far as –82 
and +105 kb from the start site (Figure 3).
To increase the robustness of the analysis, P values of over-
expressed genes were corrected for false discovery rate by the 
Benjamini–Hochberg and Bonferroni methods. Genes signifi-
cantly overexpressed (P < 0.05) after the more stringent Bonferroni 
correction were 1/3 for the HIV LTR, 1/2 for the CMV promoter, 
3/7 for the PGK promoter in both vector context, and 8/15 for the 
MLV LTR (Table 1), confirming the significant difference in the 
table 1 list of genes deregulated by γ-retroviral or lentiviral integration in t-cell clones
Vector clone target gene location
distance 
from 
tss (kb) orientation
taqman  
probe  
location z-score P value
Benjamini– 
Hochberg correction 
(P value)
Bonferroni  
correction  
(P value)
HIV 76d SIAH2 Intron 1 7.76 Forward ex 1–2 –3.67 0.0002 0.008 0.01
34c NADK Intron 1 3.95 Forward ex 1–2 –3.45 0.0006 0.008 0.03
11b CCNF Intron 8 13.70 Forward ex 8–9 –3.41 0.0007 0.008 0.03
23b RAB14 Intron 1 8.00 Forward ex 3–4 2.81 0.005 0.04 >0.05
3b FLJ25059 Intron 1 26.57 Forward ex 6–7 2.92 0.004 0.04 >0.05
146d DNMT2 Upstream –8.77 Forward ex 4–5 3.47 0.0005 0.008 0.03
∆HIV-CMV 13a TNFRSF7 Upstream –4.60 Forward ex 2–3 2.82 0.005 >0.05 >0.05
12b TRIP4 Intron 3 9.70 Forward ex 4–5 4.91 <10–6 <10–4 <10–4
∆HIV-PGK 16a CCL5 Upstream –19.44 Reverse ex 2–3 –3.77 0.0002 0.006 0.02
12b APEH Downstream 90.90 Forward ex 12–13 –3.30 0.0009 0.03 >0.05
11b GTF2H3 Intron 8 24.00 Reverse ex 9–10 –3.11 0.002 0.03 >0.05
2b PMPCA Intron 4 2.37 Forward ex 7–8 –2.84 0.0046 >0.05 >0.05
12a TBC1D19 Intron 1 26.72 Reverse ex 19–20 2.84 0.004 >0.05 >0.05
3b ZDHHC21 Intron 1 2.44 Forward ex 2–3 3.20 0.001 0.03 >0.05
2b CARD9 Upstream –39.37 Reverse ex 10–11 5.17 <10–6 <10–4 <10–4
8a SLC25A36 Intron 4 27.14 Reverse ex 5–6 7.35 <10–6 <10–6 <10–6
∆HIV-MLV 21a RNH1 Intron 1 1.79 Reverse ex 9–10 3.34 0.0008 0.006 >0.05
10a ST6GALNAC4 Downstream 15.52 Forward ex 4–5 3.54 0.0004 0.003 0.03
12a C12orf40 Intron 1 0.51 Forward ex 6–7 3.68 0.0002 0.002 0.02
25a CASC4 Intron 1 15.37 Reverse ex 10 4.16 0.0003 0.0003 0.003
21a DHX29 Intron 5 12.47 Forward ex 25–26 4.22 <10–4 0.0003 0.002
29a CHAF1B Upstream –9.24 Reverse ex 8–9 4.65 <10–6 <10–4 0.0003
13a PTCH2 Upstream –82.09 Reverse ex 19–20 4.97 <10–6 <10–4 <10–4
9a DNAJC13 Intron 11 42.48 Forward ex 48–49 5.04 <10–6 <10–6 <10–4
20a TRIM69 Upstream –20.28 Reverse ex 5–6 5.69 <10–6 <10–6 <10–6
6a RNF11 Intron 3 1.54 Reverse ex 3 7.10 <10–6 <10–6 <10–6
21a CDC42EP2 Upstream –27.18 Reverse ex 1–2 9.08 <10–6 <10–6 <10–6
MLV 13a MIA2 Upstream –3.07 Reverse ex 4–5 3.21 0.001 0.03 >0.05
3a SNARK Intron 1 6.93 Forward ex 5–6 3.29 0.0009 0.03 >0.05
42a LY64 Upstream –25.33 Reverse ex 2–3 3.63 0.0003 0.01 >0.05
47a THRAP2 Intron 2 105.00 Reverse ex 9–10 4.50 <10–6 0.0006 0.0006
∆MLV-PGK 18a BRF2 Upstream –0.93 Reverse ex 3–4 3.24 0.001 0.04 >0.05
43a WWP2 Upstream –0.60 Reverse ex 24–25 3.24 0.001 0.04 >0.05
29a C5orf27 Upstream –17.02 Reverse ex 3–4 7.59 <10–6 <10–6 <10–6
Abbreviations: CMV, cytomegalovirus; ex, exon; HIV, human immuno-deficiency virus; kb, kilobases; MLV, Moloney leukemia virus; PGK, phosphoglycerate kinase; 
TSS, transcription start site.
Vectors are identified in Figure 1a. Relative expression values, determined by Taqman PCR, are indicated by red dots in Figure 1c.
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frequency of upregulation between the MLV LTR and the other 
promoter/enhancer elements.
lV vectors cause both up- and downregulation of 
gene expression
Unexpectedly, the HIV and ΔHIV-PGK vectors induced downreg-
ulation as often as upregulation, i.e., in 3/50 (6.0%) and 4/106 (3.7%) 
tested genes, respectively (z-score <–2.81, P < 0.005, Figure 2b). 
Half of these downregulations were still significant (P < 0.05) 
after Bonferroni correction (Table 1). Genes were downregulated 
two- to tenfold compared to the mean of the control clone popu-
lation, and less than twofold compared to the lowest- expressing 
control clone (Figure 2b), consistent with  inactivation of only one 
allele. The PGK promoter induced no significant downregulation 
of the 94 tested genes in a SIN-RV context (ΔMLV-PGK), sug-
gesting that the LV vector backbone might have characteristics 
that favor this phenomenon. Indeed, in 4/7 cases the HIV and 
ΔHIV-PGK vectors inserted HIV-derived splicing and polyadeny-
lation signals within the downregulated gene in direct transcrip-
tional orientation and upstream from the TaqMan primer/probe 
(e.g., SIAH2 gene Figure 4), an event that might reduce transcript 
accumulation and detection by a post-transcriptional mechanism. 
In 2/7 cases, however, the vector integrated outside the target gene 
(e.g., CCL5 gene Figure 4), indicating reduced transcription as the 
likely cause of downregulation.
dIscussIon
Insertion of RV vectors carrying transcriptional and post-
 transcriptional regulatory elements in the human genome 
can  perturb the normal regulation of genes surrounding the 
 integration sites, and eventually induce clonal selection or neo-
plastic transformation in animal models6,15 or in patients.1,2,7–9 
The choice of a vector type/design and of a promoter/enhancer 
 element to drive a therapeutic transgene must take into account 
the potential genotoxicity of the integrated provirus in the target 
cell. This can be assayed in a variety of tests, which include induc-
tion of tumors in vitro16 or in vivo.14 These parameters, however, 
are highly dependent on the choice of the animal model or the 
test cell line, and are not necessarily predictive of the potential 
consequences of vector integration in different human cells, 
genetic backgrounds, and diseases contexts. The overall influence 
of a given provirus on the expression of surrounding genes pro-
vides an additional readout of its potential genotoxicity, which is 
independent from the biological consequences of the insertion 
event, e.g., clonal selection or tumor induction. We have devel-
oped a reliable assay to determine the a priori potential for gene 
deregulation of different vectors at clonal level and in a clinically 
relevant target cell, e.g., human primary T-lymphocytes. Very few 
studies have addressed this important safety parameter in the 
past17,18 and none has done so for different vectors and transcrip-
tional regulatory elements. Our study shows that transcription-
ally active enhancer/promoter  elements may perturb expression 
of cellular genes at considerable distance from a RV insertion site, 
 independently from the  vector type (RV or LV) and design (LTR-
based or SIN). A strong enhancer element such as the MLV LTR 
 interferes with normal gene regulation more often, at a longer 
range and in a more pronounced fashion both in an MLV and in 
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a SIN-HIV context, while a weaker enhancer such as PGK has a 
lower activity in both  vector contexts. For all vectors, upregula-
tion was observed in genes expressed at any basal level in T cells, 
indicating that enhancer insertion can activate inactive genes as 
well as overexpress active ones. Interestingly, LV vectors carrying 
either a wild-type or a SIN LTR induced downregulation of gene 
expression at a significant frequency, a phenomenon not observed 
in the case of RV vectors. In three quarter of the cases, the vectors 
integrated in direct transcriptional orientation within an intron 
of the downregulated gene, where the insertion of HIV-derived 
splicing and polyadenylation signals may cause aberrant splicing 
and/or premature transcript termination. Post-transcriptional 
gene inactivation may, therefore, be a relatively frequent con-
sequence of LV integration, possibly underestimated by a PCR-
based assay that would detect decreased transcript  levels only 
when the specific probe/primer pairs are located downstream 
from the viral integration site. In some cases, however, reduced 
transcript accumulation may have been caused only by tran-
scriptional mechanisms, since the vector integrated outside the 
 transcribed portion of the target gene.
This study shows that the genotoxic potential of a RV vector 
depends on the activity of the elements used to drive transgene 
expression rather than on the vector type. The SIN design,  typical 
of LV vectors, removes the enhancers contained in the LTR and 
reduces the potential for perturbation of gene expression. A SIN 
vector, however, can induce upregulation of gene expression at 
high frequency if a potent viral enhancer, such as the MLV LTR, 
or a cellular enhancer, such as the β-globin locus control region,17 
is used to drive transgene expression. The SIN design can indeed 
be applied also to RV vectors, where it was reported to reduce 
the risk of insertional oncogenesis compared to an LTR-based 
design.16 Therefore, LV vectors are not inherently safer than RV 
vectors in terms of their potential to perturb gene expression in 
target cells, which appears to depend only on the activity of the 
elements used to drive transgene expression. It must be stressed, 
however, that a perturbation assay measures only one of the 
 factors contributing to the overall genotoxic potential of a RV 
vector. An additional crucial factor is provided by the different 
propensity of LV and RV vectors to target potentially  sensitive 
regions of the genome. In fact, MLV-based vectors target pro-
moters and regulatory elements, and integrate in the proximity 
of growth-controlling genes, at a much higher frequency than 
HIV-based vectors.4,5 This is expected to increase the relative 
genotoxic potential of RV vectors by a significant factor, indepen-
dently from the transcriptional activity of the internal  elements. 
On the other hand, gene inactivation may largely depend on the 
frequency of intragenic insertion and the strength of the splice/
polyadenylation signal carried by the vector, both higher in the 
case of LV  vectors. Insertion of strong, HIV-derived splicing 
or polyadenylation signals within a gene might indeed reduce 
transcript detection by a post-transcriptional mechanism. Gene 
inactivation could represent a specific risk of LV vectors, which 
contain stronger splicing signals than most γ-RV vectors, and 
have a higher propensity to integrate within genes. Genotoxicity 
should, therefore, be assessed in a comprehensive fashion in 
relevant target cells and by a variety of parameters. We propose 
to measure the potential for deregulation of gene expression as 
one of these parameters. The automated quantitative PCR–based 
assay described in this study is relatively inexpensive and easy 
to perform, and could be easily standardized and validated for 
 preclinical or follow-up assessment of  vector genotoxicity.
MAterIAls And MetHods
RV vectors. Vectors pHR2pptGFP-PGKΔNGFrwpre (HIV), pRRLsin-18.
pptCMV-GFPwpre (ΔHIV-CMV), pRRLsin-18.pptPGK-GFPwpre 
(ΔHIV-PGK), pRRLsin-18.pptMLV-GFPwpre (ΔHIV-MLV), SFCMM2 
(MLV), and pSRS11.PGK.GFP.wpre (ΔMLV-PGK) were previously 
described.5,11,16 MLV vector supernatants were obtained from a stable, 
Am12-derived amphotropic packaging cell line.19 The ΔMLV-PGK  vector 
was pseudotyped with VSV-G by transient cotransfection of 293T cells 
with MLV Gag-Pol and VSV-G expression plasmids. VSV-G-pseudotyped 
LV vector supernatants were produced by transient transfection of 293T 
cells, as previously described.5
T-cell isolation, transduction, and cloning. Ficoll-Hypaque mononu-
clear cell fractions were isolated from cord blood or peripheral blood from 
healthy donors, stimulated in culture with X-VIVO-15 (BioWhittaker, 
Verviers, Belgium) supplemented with 10% human serum (Cambrex 
BioScience, Walkersville, MD), 50 U/ml IL-2 (Chiron, Emeryville, CA), 
and 25 U/ml IL-7 (ImmunoTools, Friesoythe, Germany), in the presence 
of CD3/CD28 T-cell expander (Dynal, Lake Success, NY) at a ratio of 0.5 
bead/cell for 3 days, transduced by spinoculation and cloned by limiting 
dilution in 96-well plates at a concentration of 0.3–1 cells/well, as previ-
ously described.19
Analysis of RV integration sites. Integration sites were cloned by 
LM-PCR as described previously.20,21 Briefly, genomic DNA was extracted 
from 106 infected cells and digested with MseI and a second enzyme to 
prevent  amplification of internal 5′ LTR fragments (PstI for RV vectors 
and SacI/NarI for LV vectors). An MseI double-stranded linker was then 
ligated, and LM-PCR performed with nested primers specific for the linker 
and the 3′ LTR (MLV: 5′-GACTTGTGGTCTCGCTGTTCCTTGG-3′ and 
5′-GGTCTCCTCTGAGTGATTGACTACC-3′; HIV: 5′-AGTGCTTC 
AAGTAGTGTGTGCC-3′ and 5′-GTCTGTTGTGTGACTCTGGTAA 
C-3′). PCR products were shotgun-cloned (TOPO TA cloning kit; 
Invitrogen; Carlsbad, CA) into libraries of integration junctions and 
sequenced. A valid integration contained the MLV or HIV nested primer, 
the entire MLV or HIV genome, and the linker nested primer. Sequences 
between the 3′ LTR and the linker primers were mapped onto the human 
genome (UCSC Human Genome Project Working Draft, hg17) using 
Blat22 requiring a 98% identity over the entire sequence length and select-
ing the best hit. The absolute genomic coordinates of the integration sites 
were defined as a result of the combination of genomic alignment and 
vector relative orientation data.
Gene expression profiling of mock-transduced T cells was deter-
mined in triplicate by Affymetrix HG-U133_Plus_2 Gene Chip analysis, 
as previously described.11 Expression values were divided in four 
classes, i.e., absent, low (<25th percentile in a normalized distribution), 
intermediate (>25th and <75th percentile), and high (>75th percentile).
Quantitative analysis of gene expression. Total RNA (100 ng) was reverse 
transcribed using the cDNA Archive kit (Applied Biosystems). TaqMan 
PCR reactions were carried out onto custom 7900 TaqMan low-density 
arrays (“Assay on Demand,” Applied Biosystems) on an ABI PRISM 7900 
HT system. Gene expression levels were determined using the compara-
tive CT method of relative quantification. ΔCTs were calculated using the 
CT of the glyceraldehyde-3-phosphate dehydrogenase gene as an internal 
control, and normalized (ΔΔCTs) using the median of ΔCTs in all samples 
as calibrator. The RQ of each transcript was calculated as 2–ΔΔCT, and plot-
ted as log2 values. For each gene, the RQ value in the test T-cell clone was 
856 www.moleculartherapy.org  vol. 17 no. 5 may 2009 
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compared with the mean ± SD of a control cell population (10 < n < 31), 
and z-scores determined as ( SD .x x− )  P values were corrected for false 
discovery rate by the Benjamini–Hockberg and Bonferroni methods.
suppleMentAry MAterIAl
Figure S1. (A-F) Quantitative PCR analysis of the expression in 
 individual T-cell clones of all the analyzed genes in a window of ±100-
kb around the integration sites of the RV and LV vectors indicated in 
Figure 1A.
Figure S2. Analysis of lentiviral integration sites.
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